Profile | GDS2987 / GI_24432075-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 16.5 | 49 |
GSM215244 | HMVEC_vehicle_rep2 | 28 | 56 |
GSM215253 | HMVEC_vehicle_rep3 | 3.7 | 13 |
GSM215254 | HMVEC_atorvastatin_rep1 | 13.8 | 35 |
GSM215282 | HMVEC_atorvastatin_rep3 | 10.4 | 24 |
GSM215344 | HMVEC_atorvastatin_rep2 | 31.3 | 58 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 20.2 | 37 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 3.3 | 6 |
GSM215294 | HMVEC_SLx2119_rep1 | 16 | 49 |
GSM215295 | HMVEC_SLx2119_rep2 | 41.2 | 60 |
GSM215296 | HMVEC_SLx2119_rep3 | 50 | 61 |
GSM215297 | PASMC_vehicle_rep1 | 10.7 | 17 |
GSM215298 | PASMC_vehicle_rep2 | 30 | 43 |
GSM215310 | PASMC_vehicle_rep3 | 42.9 | 56 |
GSM215311 | PASMC_atorvastatin_rep1 | 41.8 | 57 |
GSM215312 | PASMC_atorvastatin_rep2 | 22.2 | 34 |
GSM215313 | PASMC_atorvastatin_rep3 | 37.7 | 49 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 42.9 | 57 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 53.3 | 65 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 45.1 | 59 |
GSM215327 | PASMC_SLx2119_rep1 | 31.7 | 48 |
GSM215328 | PASMC_SLx2119_rep2 | 33.8 | 52 |
GSM215329 | PASMC_SLx2119_rep3 | ||
GSM215330 | Fibroblasts_vehicle_rep1 | 7.4 | 18 |
GSM215331 | Fibroblasts_vehicle_rep2 | 28.5 | 58 |
GSM215332 | Fibroblasts_vehicle_rep3 | ||
GSM215333 | Fibroblasts_atorvastatin_rep1 | 16.1 | 40 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 21.4 | 50 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 35.7 | 61 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 21 | 54 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 14.8 | 43 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 23.3 | 53 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 11.7 | 33 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 14.2 | 38 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 17.4 | 41 |